ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

ASCO Survey Finds Docs’ Quality Time With Patients Down, Due To Paperwork.

June 22, 2001

Research Opportunities On Diet, Nutrition Outlined To NCAB

July 11, 1975

SWOG Wins NCI Grant Renewal For Six Years

April 16, 2010

In Brief: Howard Skipper Retires; Oglesby To Head SRI; John Montgomery Named Kettering-Meyer Director

December 19, 1980

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

August 31, 1979